Clinical Trial Update: Enbrel Liquid Immunogenicity Protocol [Phase 3]

View source ↗

Summary

An update on the Phase 3 immunogenicity protocol for Enbrel (etanercept) in rheumatoid arthritis, with the trial status shown as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED